 This study will compare this new therapeutic approach IMRT directly with a standard treatment option for prostate cancer patients PIPB. This trial will allow us to determine how the toxicities of these treatments compare with each other and, if successful, will potentially lead to a larger study which will analyse how the outcomes of these therapeutic interventions compare. We hope that this trial will make an important contribution to the care and future management of patients with prostate cancer. 